Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Outcomes in patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy(NAC) have been widely studied; however, there is limited information on responses to chemotherapy among patients with non-HGSC. The aim of this study was to compare the survival outcomes of patients with advanced-stage non-HGSC and HGSC treatedwith NAC. Materials and Methods: This study was a retrospective analysis of patients with advanced-stage ovarian cancer treated at YonseiCancer Hospital between 2006 and 2017. The demographics, chemotherapy response, and survival rates were compared betweenpatients with non-HGSC and those with HGSC. Results: Among 220 patients who underwent NAC, 25 (11.4%) patients had non-HGSC histologic subtypes, and all received ataxane-platinum combination regimen for NAC. Patients with non-HGSC had lower baseline cancer antigen-125 levels (p<0.001),poorer response rates (p<0.001), lower rates of optimal cytoreduction (p=0.003), and poorer progression-free survival (PFS) (medianPFS 10.3 months vs. 18.3 months; p=0.009) and overall survival (OS) (median OS 25.5 months vs. 60.6 months; p<0.001),compared to those with HGSC. In multivariate analysis, non-HGSC was a negative prognostic factor for both PFS [hazard ratio(HR), 3.19; 95% confidence interval (CI), 1.73–5.88] and OS (HR, 4.22; 95% CI, 2.07–8.58). Conclusion: In this study, poorer survival outcomes were observed in patients who underwent NAC for treatment of non-HGSCversus those treated for HGSC. Different treatment strategies are urgently required to improve survival outcomes for patients withnon-HGSC undergoing NAC.
Abstract
Purpose: Outcomes in patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy(NAC) have been widely studied; however, there is limited information on responses to chemotherapy among patients with non-HGSC. The aim of this study was to compare the survival outcomes of patients with advanced-stage non-HGSC and HGSC treatedwith NAC. Materials and Methods: This study was a retrospective analysis of patients with advanced-stage ovarian cancer treated at YonseiCancer Hospital between 2006 and 2017. The demographics, chemotherapy response, and survival rates were compared betweenpatients with non-HGSC and those with HGSC. Results: Among 220 patients who underwent NAC, 25 (11.4%) patients had non-HGSC histologic subtypes, and all received ataxane-platinum combination regimen for NAC. Patients with non-HGSC had lower baseline cancer antigen-125 levels (p<0.001),poorer response rates (p<0.001), lower rates of optimal cytoreduction (p=0.003), and poorer progression-free survival (PFS) (medianPFS 10.3 months vs. 18.3 months; p=0.009) and overall survival (OS) (median OS 25.5 months vs. 60.6 months; p<0.001),compared to those with HGSC. In multivariate analysis, non-HGSC was a negative prognostic factor for both PFS [hazard ratio(HR), 3.19; 95% confidence interval (CI), 1.73–5.88] and OS (HR, 4.22; 95% CI, 2.07–8.58). Conclusion: In this study, poorer survival outcomes were observed in patients who underwent NAC for treatment of non-HGSCversus those treated for HGSC. Different treatment strategies are urgently required to improve survival outcomes for patients withnon-HGSC undergoing NAC.
참고문헌 (24)
- 임명철, "Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010", Journal of Gynecologic Oncology, 24(4), pp.298~302 (2013), 대한부인종양학회
- 이정윤, "Trends in gynecologic cancer mortality in East Asian regions", Journal of Gynecologic Oncology, 25(3), pp.174~182 (2014), 대한부인종양학회
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2013", Cancer Research and Treatment, 45(1), pp.15~21 (2013), 대한암학회[DOI]
- 김세익, "Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012", Journal of Gynecologic Oncology, 27(1), pp.1~10 (2016), 대한부인종양학회
- del Carmen MG, "Carcinosarcoma of the ovary: a review of the literature", Gynecol Oncol, 125, pp.271~277 (2012)[DOI]
- Hosono S, "Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery", Int J Clin Oncol, 16, pp.524~532 (2011)[DOI]
- Melamed A, "Associations between residual disease and survival in epithelial ovarian cancer by histologic type", Gynecol Oncol, 147, pp.250~256 (2017)[DOI]
- Mackay HJ, "Prognostic relevance of uncommon ovarian histology in women with stage III", IV epithelial ovarian cancer, 2010, pp.20, 945~952
- Schnack TH, "Demographic clinical and prognostic factors of primary ovarian adenocarcinomas of serous and clear cell histology-A comparative study", Int J Gynecol Cancer, 26, pp.82~90 (2016)[DOI]
- Simons M, "Relatively poor survival of mucinous ovarian carcinoma in advanced stage: a systematic review and meta-analysis", Int J Gynecol Cancer, 27, pp.651~658 (2017)[DOI]
- Grabowski JP, "Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase", Gynecol Oncol, 140, pp.457~462 (2016)[DOI]
- Sugiyama T, "Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017", GCIG Trial, 2016, pp.34, 2881~2887
- Takakura S, "Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study", Int J Gynecol Cancer, 20, pp.240~247 (2010)[DOI]
- Gershenson DM, "Hormonal maintenance therapy for women with lowgrade serous cancer of the ovary or peritoneum", J Clin Oncol, 35, pp.1103~1111 (2017)[DOI]
- Groen RS, "Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all", Gynecol Oncol, 136, pp.373~383 (2015)[DOI]
- Kehoe S, "Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial", Lancet, 386, pp.249~257 (2015)[DOI]
- Vergote I, "Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer", N Engl J Med, 363, pp.943~953 (2010)[DOI]
- Chung YS, "Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer", PLoS One, 12, pp.e0183754.`~ (2017)[DOI]
- Fagotti A, "Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience", Gynecol Oncol, 131, pp.341~346 (2013)[DOI]
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)[DOI]
- Prat J, "Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features", Virchows Arch, 460, pp.237~249 (2012)[DOI]
- Galic V, "Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways", Curr Cancer Drug Targets, 13, pp.698~707 (2013)[DOI]
- Gilks CB, "Ovarian carcinoma pathology and genetics: recent advances", Hum Pathol, 40, pp.1213~1223 (2009)[DOI]
- Lalwani N, "Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment", Radiographics, 31, pp.625~646 (2011)[DOI]